Evidence map›Paper›PMID 41997150›Full record

ArticleStem cell reports2026

Organoid phenotypic screening identified glycyrrhizin that confers protection against tumor necrosis factor-induced cell death.

Yu Takahashi, Zhongwei Zhang, Izumi Tanaka, I-Ting Lee, Jincheng He, Yurina Koura, Shintaro Sato, Hirotatsu Kojima, Takayoshi Okabe, Hiroshi Kiyono and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cell reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yu TakahashiFood Biochemistry Laboratory, Department of Applied Biological Chemistry, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo 113-8657, Japan. Electronic address: ayutaka@g.ecc.u-tokyo.ac.jp.
Zhongwei ZhangDepartment of Innovative Medicine, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan.
Izumi TanakaDepartment of Innovative Medicine, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan.
I-Ting LeeFood Biochemistry Laboratory, Department of Applied Biological Chemistry, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo 113-8657, Japan.
Jincheng HeDepartment of Innovative Medicine, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan.
Yurina KouraFood Biochemistry Laboratory, Department of Applied Biological Chemistry, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo 113-8657, Japan.
Shintaro SatoDepartment of Microbiology and Immunology, School of Pharmaceutical Sciences, Wakayama Medical University, Wakayama 640-8156, Japan; Department of Virology, Research Institute for Microbial Diseases, Osaka University, Osaka 565-0871, Japan.
Hirotatsu KojimaDrug Discovery Initiative, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo 113-0033, Japan.
Takayoshi OkabeDrug Discovery Initiative, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo 113-0033, Japan.
Hiroshi KiyonoSynergy Institute for Futuristic Mucosal Vaccine Research and Development, Chiba University, Chiba 260-8670, Japan; Chiba University-University of California San Diego Center for Mucosal Immunology, Allergy and Vaccine (CU-UCSD cMAV), Department of Medicine, School of Medicine, San Diego, CA 92093, USA; Department of Human Mucosal Vaccinology, Chiba University Hospital, Chiba 260-8670, Japan.
Takashi SasakiNutri-Life Science Laboratory, Department of Applied Biological Chemistry, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo 113-8657, Japan.
Yoshio YamauchiFood Biochemistry Laboratory, Department of Applied Biological Chemistry, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo 113-8657, Japan.
Yosuke KurashimaDepartment of Innovative Medicine, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan; Synergy Institute for Futuristic Mucosal Vaccine Research and Development, Chiba University, Chiba 260-8670, Japan; Chiba University-University of California San Diego Center for Mucosal Immunology, Allergy and Vaccine (CU-UCSD cMAV), Department of Medicine, School of Medicine, San Diego, CA 92093, USA.
Ryuichiro SatoNutri-Life Science Laboratory, Department of Applied Biological Chemistry, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo 113-8657, Japan. Electronic address: roysato@g.ecc.u-tokyo.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human organoids are considered physiological models that reflect human physiology; however, their applications in drug screening studies are limited. To develop a fundamental treatment for recurrent Crohn's disease (CD), in which tumor necrosis factor (TNF) is a key pathogenic factor, we conducted phenotypic drug screening to prevent TNF-induced cell death in human intestinal epithelial organoids. Glycyrrhizin, a natural product of licorice root, dose-dependently blocked TNF-induced cell death in organoids but not in TNF-sensitive L929 cells; L929 cells exhibited necroptosis, whereas organoid-derived cells preferentially showed apoptosis upon TNF treatment, determining the specificity of glycyrrhizin. Glycyrrhizin inhibited downstream caspase-8 signaling, which is essential for TNF-dependent apoptosis, and ameliorated intestinal inflammation in vivo. These results demonstrate that glycyrrhizin may be a novel therapeutic compound for CD and highlight the importance of using organoids for phenotypic drug screening.

Indexed as

Glycyrrhizic AcidOrganoidsTumor Necrosis Factor-alphaAnimalsApoptosisCaspase 8Cell DeathCell LineDrug Evaluation, PreclinicalHumansMicePhenotypeSignal TransductionCaspase 8Glycyrrhizic AcidTumor Necrosis Factor-alphaapoptosisCrohn’s diseaseglycyrrhizinhuman intestinal organoidsphenotypic screeningtumor necrosis factor

Identifiers

PMID41997150
PMCPMC13163214

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.